We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




New Protein MRI Contrast Agent Developed for Liver Cancer Imaging

By MedImaging International staff writers
Posted on 01 Jun 2015
Print article
The results of a study published in the May, 13, 2015, online issue of the Proceedings of the National Academy of Sciences of the United States of America (PNAS) reveal the development of a novel, and much more effective Magnetic Resonance Imaging (MRI) contrast agent, named ProCA32.

The researchers from the Georgia State University (Atlanta, GA, USA) and other institutions in Atlanta anticipate that the new protein-based MRI contrast agent and associated imaging methodology could help earlier detection of liver cancer, and other liver diseases. Existing contrast agents and imaging techniques are not sensitive and robust enough to diagnose primary and metastatic liver cancers early enough, and show poor treatment responses, and result in high mortality rates.

ProCA32 shows high stability for Gadolinium (Gd3+) and a 1011-times increased selectivity for Gd3+ over Zinc (Zn2+) compared with existing contrast agents, and can be used to detect early-stage micro-metastatic liver tumors. Using T1- and T2-weighted and T2/T1 ratio robust MRI imaging, the researchers were able to detect early liver metastases ∼0.24 mm in diameter. The current detection size limit is 10–20 mm.

The new contrast agent has additional properties that make it suitable for high-quality imaging, and could be a breakthrough, not only for early detection of primary and metastatic liver cancers, but also for treatment monitoring, and guiding therapeutic interventions, such as drug delivery.

Related Links:

Georgia State University


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Brachytherapy Planning System
Oncentra Brachy
Oncology Information System
RayCare
Compact C-Arm with FPD
Arcovis DRF-C R21

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.